lncRNA CASC2 Enhances 131I Sensitivity in Papillary Thyroid Cancer by Sponging miR‐155
L Tao, P Tian, L Yang, X Guo - BioMed Research International, 2020 - Wiley Online Library
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131I) is a common option …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131I) is a common option …
[PDF][PDF] Research Article lncRNA CASC2 Enhances 131 I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155
L Tao, P Tian, L Yang, X Guo - Age (years), 2020 - scienceopen.com
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131I) is a common option …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131I) is a common option …
[HTML][HTML] lncRNA CASC2 Enhances 131I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155
L Tao, P Tian, L Yang, X Guo - BioMed Research International, 2020 - ncbi.nlm.nih.gov
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
lncRNA CASC2 Enhances 131I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155
L Tao, P Tian, L Yang, X Guo - BioMed research …, 2020 - pubmed.ncbi.nlm.nih.gov
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
lncRNA CASC2 Enhances 131I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155
T Ling, P Tian, L Yang, X Guo - BioMed Research International, 2020 - search.proquest.com
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
lncRNA CASC2 Enhances 131I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155.
L Tao, P Tian, L Yang, X Guo - BioMed Research …, 2020 - search.ebscohost.com
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (< sup> 131 I) is a common …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (< sup> 131 I) is a common …
lncRNA CASC2 Enhances 131I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155.
L Tao, P Tian, L Yang, X Guo - Biomed Research International, 2020 - europepmc.org
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine (131 I) is a common option …
lncRNA CASC2 Enhances [sup. 131] I Sensitivity in Papillary Thyroid Cancer by Sponging miR-155.
L Tao, P Tian, L Yang, X Guo - BioMed Research International, 2020 - go.gale.com
Long noncoding RNA cancer susceptibility candidate 2 (CASC2) has been reported to play
an anticancer role in papillary thyroid cancer (PTC). Radioiodine ([sup. 131] I) is a common …
an anticancer role in papillary thyroid cancer (PTC). Radioiodine ([sup. 131] I) is a common …